Novo Nordisk Faces a High-Stakes Balancing Act: Wegovy Pill Approval vs. Escalating Cyber Threats
Novo Nordisk ended a week of stark contrasts with its shares stuck near EUR 38.90 — a modest…
Novo Nordisk’s Balancing Act: Weighing a Lost CVS Advantage Against a Make-or-Break Data Readout
CVS Caremark revokes Wegovy’s preferred status on formulary, opening door for Eli Lilly. Novo Nordisk shares fall 40%…
Buybacks, Greenland, and a Cash-Rich Paradox
European Lithium launches a share buyback amid Greenland regulatory bottleneck for its Tanbreez rare earths project. The firm…